China’s NMPA approves Eylea 8 mg for wet age-related macular degeneration: Berlin Friday, May 23, 2025, 09:00 Hrs [IST] The Center for Drug Evaluation (CDE) of China’s National Medical Products ...

Meanwhile, Regeneron’s newer and higher-dose version of the eye med, Eylea HD, grew U.S. sales 54% over the same period in 2024 to $307 million.

“With these pivotal results in retinal vein occlusion, Eylea HD with extended dosing has again met the high bar of vision gains and safety seen with standard-of-care Eylea,” said George D. Yancopoulos ...

FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The ...

EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting ...

Regeneron's phase III study evaluating Eylea HD against stand-of-care Eylea treatment meets the primary endpoint of non-inferior visual gain in RVO patients.

Despite the threats from Amgen and Roche, Eylea HD’s potential approval in RVO—as well as a launch as a prefilled syringe—could prompt “a little bit of an acceleration” for 2025 sales ...

EYLEA HD demonstrated non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 weeks Safety data remains consistent with the ...

Eylea is still a very important product for Regeneron. U.S. sales and collaboration profits from ex-U.S. partner Bayer accounted for 51% of total revenues in Q3.

Sales for the Eylea franchise were $2.5 billion in the quarter, up 4% year on year; $392 million of that was Eylea high-dose sales in the US.

U.S. drugmaker Regeneron Pharmaceuticals on Thursday reported weaker-than-expected quarterly sales of the higher dose version of its blockbuster eye disease drug Eylea, sending its shares down 9%.